| Identification | Back Directory | [Name]
st-1535 | [CAS]
496955-42-1 | [Synonyms]
st-1535
2-Butyl-9-methyl-8-(2H-1,2,3-triazol-2-yl)-9H-purin-6-amine
9H-Purin-6-amine, 2-butyl-9-methyl-8-(2H-1,2,3-triazol-2-yl)- | [Molecular Formula]
C12H16N8 | [MDL Number]
MFCD27987937 | [MOL File]
496955-42-1.mol | [Molecular Weight]
272.31 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 5mg/mL,DMSO: 5mg/mL,DMSO:PBS (pH 7.2) (1:9): 0.1mg/mL | [form ]
A solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
ST 1535 is a potent and orally active A2A adenosine receptor antagonist. ST 1535 shows antiparkinsonian activity and antitremorigenic effects. ST 1535 has the potential for the research of Parkinson’s disease[1][2]. | [in vivo]
ST 1535 (0, 5, 10 mg/kg; p.o.) antagonizes catalepsy induced by i.c.v. administration with the A2A adenosine agonist CGS 21680.html" class="link-product" target="_blank">CGS 21680 (HY-13201)[1].
ST 1535 (10, 20, 40 mg/kg; i.p.) increases the number of contralateral turns induced by l-DOPA (HY-N0304) in rats[2]. | Animal Model: | 5-6 weeks CD1 male mice[1] | | Dosage: | 0, 5, 10 mg/kg | | Administration: | P.o. | | Result: | Antagonized catalepsy induced by i.c.v. administration with the A2A adenosine agonist CGS 21680. |
| Animal Model: | Male Sprague Dawley rats[2] | | Dosage: | 10, 20, 40 mg/kg | | Administration: | I.p. | | Result: | Significantly increased the number of contralateral turns induced by l-DOPA (3 mg/kg i.p.) at 20 and 40 mg/kg. |
| [IC 50]
A2a adenosine receptor | [storage]
Store at -20°C | [References]
[1] Stasi MA, et al. ST 1535: a preferential A2A adenosine receptor antagonist. Int J Neuropsychopharmacol. 2006 Oct;9(5):575-84. DOI:10.1017/S1461145705006188
[2] Tronci E, et al. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol. 2007 Jul 2;566(1-3):94-102. DOI:10.1016/j.ejphar.2007.03.021 |
|
|